Double-blind, placebo-controlled, randomized phase III trial of oral thalidomide in advanced hepatocellular carcinoma [liver cancer] with poor liver reserve

Trial Profile

Double-blind, placebo-controlled, randomized phase III trial of oral thalidomide in advanced hepatocellular carcinoma [liver cancer] with poor liver reserve

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2011

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors TTY Biopharm
  • Most Recent Events

    • 07 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top